CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high‑grade glioma

Wang,Kuanyu; Huang,Ruoyu; Li,Guanzhang; Zeng,Fan; Zhao,Zheng; Liu,Yanwei; Hu,Huimin; Jiang,Tao

doi:10.3892/or.2018.6611

CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high‑grade glioma

Authors:
- Kuanyu Wang
- Ruoyu Huang
- Guanzhang Li
- Fan Zeng
- Zheng Zhao
- Yanwei Liu
- Huimin Hu
- Tao Jiang
View Affiliations

Affiliations: Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, P.R. China, Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, P.R. China, Chinese Glioma Cooperative Group (CGCG), Beijing 100050, P.R. China
Published online on: August 1, 2018 https://doi.org/10.3892/or.2018.6611
Pages: 2036-2046
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytoskeletal‑associated protein 2 (CKAP2), which is also known as tumor‑associated microtubule‑associated protein, has been reported to be dysregulated in various types of human cancer. However, the role of CKAP2 in glioma has not been fully elucidated. The present study evaluated the expression pattern of CKAP2 using the Chinese Glioma Genome Atlas microarray database, which included 301 patients, and validated the findings using The Cancer Genome Atlas RNA sequencing database. Kaplan‑Meier survival analysis, and univariate and multivariate Cox analyses, were used to estimate survival distributions. Furthermore, the biological implication of aberrant CKAP2 expression in high‑grade glioma (HGG) was investigated using Gene Ontology analysis, gene set enrichment analysis, gene set variation analysis and STRING. The results indicated that patients with HGG exhibited significantly higher CKAP2 expression levels compared with patients with low‑grade glioma in both databases. Higher expression levels of CKAP2 were significantly associated with shorter overall survival and progression‑free survival of patients with HGG. Furthermore, CKAP2 was also positively correlated with known malignant factors, including high Ki67 expression and phosphatase and tensin homolog mutations. The univariate and multivariate Cox regression analyses demonstrated that CKAP2 may be a novel independent prognostic biomarker for patients with HGG. Functional assays also indicated that CKAP2 was closely associated with the cell cycle, mitosis and cell proliferation. These results suggested that CKAP2 may be associated with tumor growth and could serve as an independent prognostic factor, particularly in patients with HGG.

View Figures

View References

1	Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY: Primary brain tumours in adults. Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Brada M, van den Bent MJ, Tonn JC and Pentheroudakis G: ESMO Guidelines Working Group: High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014. View Article : Google Scholar : PubMed/NCBI
5	Demuth T and Berens ME: Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 70:217–228. 2004. View Article : Google Scholar : PubMed/NCBI
6	Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Eng J Med. 360:765–773. 2009. View Article : Google Scholar
7	Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P and Schiffer D: Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. J Neurooncol. 131:213–222. 2017. View Article : Google Scholar : PubMed/NCBI
8	Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F and Ermani M: Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status. Cancer. 115:3512–3518. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Su HK, Zhao HF, Chen ZP and To SS: Progress in the application of molecular biomarkers in gliomas. Biochem Biophys Res Commun. 465:1–4. 2015. View Article : Google Scholar : PubMed/NCBI
10	Huse JT and Aldape KD: The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clin Cancer Res. 20:5601–5611. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hong KU, Choi YB, Lee JH, Kim HJ, Kwon HR, Seong YS, Kim HT, Park J, Bae CD and Hong KM: Transient phosphorylation of tumor associated microtubule associated protein (TMAP)/cytoskeleton associated protein 2 (CKAP2) at Thr-596 during early phases of mitosis. Exp Mol Med. 40:377–386. 2008. View Article : Google Scholar : PubMed/NCBI
12	Case CM, Sackett DL, Wangsa D, Karpova T, McNally JG, Ried T and Camps J: CKAP2 ensures chromosomal stability by maintaining the integrity of microtubule nucleation sites. PLoS One. 8:e645752013. View Article : Google Scholar : PubMed/NCBI
13	Hong KU, Kim E, Bae CD and Park J: TMAP/CKAP2 is essential for proper chromosome segregation. Cell Cycle. 8:314–324. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yoo BH, Kang DS, Park CH, Kang K and Bae CD: CKAP2 phosphorylation by CDK1/cyclinB1 is crucial for maintaining centrosome integrity. Exp Mol Med. 49:e3542017. View Article : Google Scholar : PubMed/NCBI
15	Kim YW, Eom BW, Kook MC, Kim HS, Kim MK, Hwang HL, Chandra V, Poojan S, Song Y, Koh JS, et al: Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients. Exp Mol Med. 47:e1932015. View Article : Google Scholar : PubMed/NCBI
16	Gao Y, Liu X, Li T, Wei L, Yang A, Lu Y, Zhang J, Li L, Wang S and Yin F: Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncol Rep. 37:3084–3092. 2017. View Article : Google Scholar : PubMed/NCBI
17	Kim HS, Koh JS, Choi YB, Ro J, Kim HK, Kim MK, Nam BH, Kim KT, Chandra V, Seol HS, et al: Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer. PLoS One. 9:e981602014. View Article : Google Scholar : PubMed/NCBI
18	Guo QS, Song Y, Hua KQ and Gao SJ: Involvement of FAK-ERK2 signaling pathway in CKAP2-induced proliferation and motility in cervical carcinoma cell lines. Sci Rep. 7:21172017. View Article : Google Scholar : PubMed/NCBI
19	Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli LG, et al: MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 10:1121–1131. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE, Yu-Lee LY, Kuang J and Lin SH: RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res. 13:348–357. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hayashi T, Ohtsuka M, Okamura D, Seki N, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, et al: Cytoskeleton-associated protein 2 is a potential predictive marker for risk of early and extensive recurrence of hepatocellular carcinoma after operative resection. Surgery. 155:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, et al: Molecular classification of gliomas based on whole genome gene expression: A systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 14:1432–1440. 2012. View Article : Google Scholar : PubMed/NCBI
23	Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, et al: RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
26	Asbaghi Y, Thompson LL, Lichtensztejn Z and McManus KJ: KIF11 silencing and inhibition induces chromosome instability that may contribute to cancer. Genes Chromosomes Cancer. 56:668–680. 2017. View Article : Google Scholar : PubMed/NCBI
27	Parrilla A, Cirillo L, Thomas Y, Gotta M, Pintard L and Santamaria A: Mitotic entry: The interplay between Cdk1, Plk1 and Bora. Cell Cycle. 15:3177–3182. 2016. View Article : Google Scholar : PubMed/NCBI
28	De Carli E, Wang X and Puget S: IDH1 and IDH2 mutations in gliomas. N Eng J Med. 360:2248author reply 2249. 2009. View Article : Google Scholar
29	DeAngelis LM: Brain tumors. N Eng J Med. 344:114–123. 2001. View Article : Google Scholar
30	Tsuchihara K, Lapin V, Bakal C, Okada H, Brown L, Hirota-Tsuchihara M, Zaugg K, Ho A, Itie-Youten A, Harris-Brandts M, et al: Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. Cancer Res. 65:6685–6691. 2005. View Article : Google Scholar : PubMed/NCBI
31	Kikuchi A, Fumoto K and Kimura H: The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. Br J Pharmacol. 174:4651–4665. 2017. View Article : Google Scholar : PubMed/NCBI
32	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RAF, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
33	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re3532016. View Article : Google Scholar
34	Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu WW, Wang K, Gao L, Qi S and Lu YT: miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. J Hematol Oncol. 11:702018. View Article : Google Scholar : PubMed/NCBI
35	Jantas D, Grygier B, Golda S, Chwastek J, Zatorska J and Tertil M: An endogenous and ectopic expression of metabotropic glutamate receptor 8 (mGluR8) inhibits proliferation and increases chemosensitivity of human neuroblastoma and glioma cells. Cancer Lett. 432:1–16. 2018. View Article : Google Scholar : PubMed/NCBI
36	Guo B, Sheng Z, Hu D, Li A, Xu S, Manghnani PN, Liu C, Guo L, Zheng H and Liu B: Molecular engineering of conjugated polymers for biocompatible organic nanoparticles with highly efficient photoacoustic and photothermal performance in cancer theranostics. ACS Nano. 11:10124–10134. 2017. View Article : Google Scholar : PubMed/NCBI